Literature DB >> 6247967

In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine).

K O Smith, W L Kennell, R H Poirier, F T Lynd.   

Abstract

In vitro passage of the Patton strain of herpes simplex virus type 1 (HSV-1-P) in the presence of acycloguanosine (ACG) led to the emergence of a highly drug-resistant strain (HSV-1-P-ACG-R). Over 1% of virions in 6 of 15 HSV strains tested were able to form plaques in the presence of 10 mumol of ACG on first exposure to the drug. Therefore, there exists among HSV strains a broad range of susceptibilities to ACG, and some strains contain particles which are partially resistant to ACG before ever contacting the drug. HSV-1-P-ACG-R was partially resistant to iododeoxyuridine; conversely, iododeoxyuridine-resistant virus was highly resistant to ACG. ACG-resistant virus (HSV-1-P-ACG-R) was equal to its parent strain (HSV-1-P) in susceptibility to adenine arabinoside. The HSV-1-P-ACG-R strain produced corneal lesions in rabbits which were completely refractory to topical treatment with 1% unguent ACG, but responsive to 3% ACG. Partially resistant HSV could be isolated from the eyes of rabbits infected with ACG-susceptible virus and treated topically with either 1 or 3% ACG for 6 days.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247967      PMCID: PMC283749          DOI: 10.1128/AAC.17.2.144

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  A physical difference between two strains of herpes simplex virus apparent on sedimentation in cesium chloride.

Authors:  B ROIZMAN; P R ROANE
Journal:  Virology       Date:  1961-09       Impact factor: 3.616

2.  Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine.

Authors:  J A Fyfe; P M Keller; P A Furman; R L Miller; G B Elion
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

3.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

4.  Effect of 9-(2-hydroxyethoxymethyl)guanine on herpesvirus-induced keratitis and iritis in rabbits.

Authors:  H E Kaufman; E D Varnell; Y M Centifanto; S D Rheinstrom
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

5.  Acyclic antimetabolite therapy of experimental herpes simplex keratitis.

Authors:  D Pavan-Langston; R Campbell; J Lass
Journal:  Am J Ophthalmol       Date:  1978-11       Impact factor: 5.258

6.  Acycloguanosine for viral pneumonia.

Authors:  J M Goldman; P M Chipping; G Agnarsdottir; D Brigden
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

7.  Comparison of activity of herpes virus inhibitors.

Authors:  P Collins; D J Bauer
Journal:  J Antimicrob Chemother       Date:  1977-03       Impact factor: 5.790

8.  Mode of antiviral action of 5-iodouracil deoxyriboside.

Authors:  A S Kaplan; T Ben-Porat
Journal:  J Mol Biol       Date:  1966-08       Impact factor: 5.469

9.  Vidarabine therapy of simple and IDU-complicated herpetic keratitis.

Authors:  D Pavan-Langston; R Buchanan
Journal:  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol       Date:  1976 Sep-Oct

10.  Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers.

Authors:  B R Jones; D J Coster; P N Fison; G M Thompson; L M Cobo; M G Falcon
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321

View more
  22 in total

1.  Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models.

Authors:  M Lipsitch; T H Bacon; J J Leary; R Antia; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice.

Authors:  R F Schinazi; J Peters; C C Williams; D Chance; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

3.  Characterization of an herpes simplex virus type 2 mutant, which is resistant to acycloguanosine and causes fusion of BSC1 cells.

Authors:  E Katz; E Margalith
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

4.  Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study.

Authors:  H B Hoh; C Hurley; C Claoue; M Viswalingham; D L Easty; P Goldschmidt; L M Collum
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

5.  Cooperative effects between two acyclovir resistance loci in herpes simplex virus.

Authors:  G Darby; M J Churcher; B A Larder
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

6.  Synergism among BIOLF-62, phosphonoformate, and other antiherpetic compounds.

Authors:  K O Smith; K S Galloway; K K Ogilvie; U O Cheriyan
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

7.  Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates.

Authors:  D S Parris; J E Harrington
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

8.  A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2.

Authors:  K O Smith; K S Galloway; W L Kennell; K K Ogilvie; B K Radatus
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

9.  Properties of a novel thymidine kinase induced by an acyclovir-resistant herpes simplex virus type 1 mutant.

Authors:  B A Larder; G Darby
Journal:  J Virol       Date:  1982-05       Impact factor: 5.103

10.  Mutations in the herpes simplex virus DNA polymerase gene can confer resistance to 9-beta-D-arabinofuranosyladenine.

Authors:  D M Coen; P A Furman; P T Gelep; P A Schaffer
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.